US 12,246,066 B2
Anti-CTLA-4 antibodies and methods of use thereof
Marc Van Dijk, Bosch En Duin (NL); Cornelia Anne Mundt, Lorrach (DE); Gerd Ritter, New York, NY (US); David Schaer, Mamaroneck, NY (US); Jedd David Wolchok, New York, NY (US); Taha Merghoub, Jersey City, NJ (US); Nicholas Stuart Wilson, San Carlos, CA (US); David Adam Savitsky, Boxford, MA (US); Mark Arthur Findeis, Lexington, MA (US); Dennis John Underwood, Lexington, MA (US); Jean-Marie Cuillerot, Somerville, MA (US); Igor Proscurshim, Carlisle, MA (US); and Olga Shebanova, Somerville, MA (US)
Assigned to AGENUS INC., Lexington, MA (US); Ludwig Institute for Cancer Research Ltd., Zurich (CH); and Memorial Sloan Kettering Cancer Center, New York, NY (US)
Filed by AGENUS INC., Lexington, MA (US); Ludwig Institute for Cancer Research Ltd., Zurich (CH); and Memorial Sloan Kettering Cancer Center, New York, NY (US)
Filed on Mar. 21, 2023, as Appl. No. 18/187,367.
Application 18/187,367 is a division of application No. 17/121,229, filed on Dec. 14, 2020, granted, now 11,638,755, issued on May 2, 2023.
Application 17/121,229 is a division of application No. 17/030,650, filed on Sep. 24, 2020, granted, now 10,912,831, issued on Feb. 9, 2021.
Application 17/030,650 is a division of application No. 15/834,290, filed on Dec. 7, 2017, granted, now 11,013,802, issued on May 25, 2021.
Claims priority of provisional application 62/431,272, filed on Dec. 7, 2016.
Prior Publication US 2023/0330225 A1, Oct. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 11/00 (2006.01); A61P 35/04 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/39558 (2013.01) [A61P 11/00 (2018.01); A61P 35/04 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/572 (2013.01); C07K 2317/21 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); Y02A 50/30 (2018.01)] 19 Claims
 
1. An isolated antibody that specifically binds to human CTLA-4, the antibody comprising:
a VH comprising the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 20; and
a VL comprising the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9,
wherein the CDRH1, CDRH2, and CDRH3 sequences of the antibody are not SEQ ID NOs: 10, 11, and 13, respectively.